Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RNA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ropivacaine HCL | Renal Carcinoma | Phase 3 · NCT07092566 | Recruiting |
| Clonidine HCL | Renal Carcinoma | Phase 3 · NCT07092566 | Recruiting |
| Ketorolac | Renal Carcinoma | Phase 3 · NCT07092566 | Recruiting |
| Vaccine | Pediatric Cancer | Phase 2 · NCT04948619 | Recruiting |
| Arylsulfatase A | Germ Cell Tumor | Phase 2 · NCT06866964 | Recruiting |
| Cisplatin | Lung Cancer Stage II | Phase 2 · NCT03141359 | Active not recruiting |
| ATR 1072 | Cardiac Glycogenosis | Phase 1/2 · NCT07738107 | Recruiting |
| Nexatoclax (LP-118) | Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 1 · NCT07614022 | Recruiting |
Also used in these trials (approved or third-party drugs, not RNA's own candidates): Epinephrine, Bupivacaine, Anastrozole, Palbociclib, Paclitaxel, Olutasidenib, Nivolumab, Metformin Hydrochloride, Etoposide, Elotuzumab, Durvalumab, Carboplatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RNA had $232.1M in cash and short-term investments on its Sep 30, 2026 balance sheet. Including the cash events since then, it holds about $293.6M pro forma, before operating spending after that date:
It burns about $14.6M/quarter from operations, an estimated runway of 60.1 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | Institution (13G, 5%+) | 1,500,000 | 6.95% | 2026-06-30 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 1,472,984 | 6.83% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 1,135,757 | 5.27% | 2026-06-30 |
| Sarah Boyce Director · +20,000 options |
Insider | 138,668 | 0.64% | 2026-09-18 |
| Kathleen P. Gallagher Chief Executive Officer and President, D · +205,000 options |
Insider | 119,729 | 0.56% | 2026-09-18 |
| Steven George Hughes Chief Medical Officer · +60,000 options |
Insider | 51,638 | 0.24% | 2026-09-18 |
| Husam Younis Chief Scientific Officer · +60,000 options |
Insider | 41,441 | 0.19% | 2026-09-18 |
| Rocio Martin Hoyos Chief Strategy Officer · +60,000 options |
Insider | 38,340 | 0.18% | 2026-09-18 |
| Brendan R. Winslow Chief Financial Officer · +60,000 options |
Insider | 36,859 | 0.17% | 2026-09-18 |
| Stephanie Kenney Chief Corporate Affairs Officer · +60,000 options |
Insider | 33,085 | 0.15% | 2026-09-18 |
| W. Michael Flanagan Director · +20,000 options |
Insider | 31,974 | 0.15% | 2026-09-18 |
| Troy Edward Wilson Director · +20,000 options |
Insider | 11,731 | 0.05% | 2026-02-26 |
Share count 21,571,507 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →